Recent Finacing
Recent Raise
Abcuro is a clinical‑stage company developing KLRG1‑targeted antibodies that deplete cytotoxic T/NK cells while sparing naïve/regulatory/central‑memory T cells; lead ABC008 in Phase 2/3 for IBM.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
